Los Angeles – September 23, 2026 -- Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War, pushing cumulative government support for its lead bacteriophage candidate AP-SA02 to approximately $32.4 million.
New funds mark first Phase 3-specific allocation under existing DoW award
The $3.7 million tranche represents the first capital earmarked specifically for Phase 3 execution under a previously announced award, following $28.7 million already disbursed. The funding flows through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command's Naval Advanced Medical Development unit, with backing from the Defense Health Agency and Joint Warfighter Medical Research Program.
AP-SA02 targets drug-resistant Staph infections with military and civilian relevance
AP-SA02, a fixed multi-phage cocktail, is being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant strains. The candidate holds Qualified Infectious Disease Product, Fast Track, and Breakthrough Therapy designations from the FDA.
Positive results from the Phase 1b/2a diSArm study (NCT05184764) were presented as a late-breaking oral presentation at IDWeek 2025 in October 2025. Armata plans to initiate a Phase 3 superiority study in the second half of 2026.
CEO frames funding as continuation of multi-stage federal collaboration
"The DoW has supported the AP-SA02 program through multiple stages of its development, and these new funds extend that support into Phase 3," said Dr. Deborah Birx, Chief Executive Officer of Armata. She noted the company intends to continue working with the DoW on potential additional Phase 3 support as the trial advances.
Complicated bacteremia carries high mortality burden across patient populations
Complicated Staph aureus bacteremia remains associated with substantial morbidity and mortality in both military and civilian populations, according to the company, underscoring demand for therapies that complement existing antibiotics amid rising antimicrobial resistance.